Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized
Advertisement

Related Content

A New Front: India’s Natco Gets State-level Nod To Sell Copies Of BMS’ Sprycel
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
Indian Pharma Lobby Says Delhi High Court Exceeded Its Authority In Restraining Hetero Dasatinib Application Due To BMS Petition
Indian Pharma Lobby Says Delhi High Court Exceeded Its Authority In Restraining Hetero Dasatinib Application Due To BMS Petition
Advertisement
UsernamePublicRestriction

Register

SC069994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel